Salix Pharmaceuticals, Ltd. news

   Watch this stock
Showing stories 1 - 10 of about 110   

Articles published

SLXP 172.81
price chart
Salix Pharmaceuticals, Ltd. Confirms Receipt of an Unsolicited Proposal from ...
RALEIGH, N.C., Mar 11, 2015 (BUSINESS WIRE) -- Salix Pharmaceuticals, Ltd. SLXP (“Salix” or the “Company”) today confirmed that it has received an unsolicited proposal from Endo International plc (“Endo”) to acquire all of the outstanding shares of ...
Endo International plc - Ordinary Shares Tries To Woo Salix Pharmaceuticals ...  Bidness ETC
Salix Pharmaceuticals Ltd: Here's Why Valeant Fought So Hard To Acquire Salix
It's already been an expensive week for Valeant Pharmaceuticals International Inc. The company announced Monday that it added roughly a billion dollars to its original bid to acquire Salix Pharmaceuticals Ltd. The new offer came after Endo ...
Valeant Wins Battle for Salix Pharmaceuticals  Wall Street Journal
As Valeant Ups Salix Buyout, Will Endo Come Back?  24/7 Wall St.
Valeant Pharmaceuticals International, Inc. Completes Tender Offer For Salix ...
LAVAL, Quebec, April 1, 2015 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced the expiration of the tender offer (the "Offer") by a subsidiary of Valeant Pharmaceuticals International ...
Valeant Pharma (VRX) Announces Results of $173/Share Salix Pharma (SLXP) Tender
Valeant Pharmaceuticals Intl Inc. Acquired Salix Pharmaceuticals Ltd.:Now What?  The Motley Fool Canada
Why Salix Pharmaceuticals, Ltd. Stock Was Clobbered in November
What: Shares of Salix Pharmaceuticals (NASDAQ:SLXP), a biopharmaceutical company that develops and acquires drugs designed to treat gastrointestinal diseases, was clobbered in November and fell by 29%, based on data from S&P Capital IQ, after the ...
Related articles »  
3 Pharma Companies Competing To Acquire Salix Pharmaceuticals, Ltd. : Who Will ...
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP), a Raleigh-based specialty pharmaceutical company focusing on innovative treatments for various gastrointestinal disorders, has been the top potential takeover target for some of the major pharmaceutical ...
Why Salix Pharmaceuticals Ltd. Stock Was Throttled
What: Salix Pharmaceuticals (NASDAQ:SLXP), a biopharmaceutical company focused on developing and acquiring drugs targeting gastrointestinal diseases, gave its own shareholders indigestion today when the stock plunged as much as 40% on ...
Salix Pharmaceuticals (SLXP) Falling In After-Hours Activity
Salix Pharmaceuticals, Ltd. (SLXP) 3Q Earnings Disappoint; Shares Tumble 38 ...  Bidness ETC
Related articles »  
Salix Pharmaceuticals, Ltd. Rises On Valeant Buyout Rumor
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) Pharmaceuticals is reportedly close to a buyout deal for Salix Pharmaceuticals, reports multiple media outlets. David Faber of CNBC was the first to report on the potential acquisition, and it was ...
Salix Pharmaceuticals, Ltd.-Valeant Pharmaceuticals Intl Inc Deal Gets Top ...  Bidness ETC
SALIX PHARMACEUTICALS, LTD. SHAREHOLDER ALERT: Rigrodsky & Long, P.A ...  PR Newswire (press release)
Do Hedge Funds Hate Salix Pharmaceuticals LTD (SLXP)?
Salix Pharmaceuticals LTD (SLXP) hedge funds sentiment decreased to 0.63 in q1 2015. Its down -0.40, from 1.03 in 2014Q4. The sentiment has dropped, as 154 investment managers increased or opened new stock positions, while 246 sold and decreased ...
Here's Why Salix Pharmaceuticals, Ltd. Executives Received Millions Even After ...
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) has paid as much as $46 million combined to two of the top executives who left the company following the accounting scandal late last year.
Salix execs – including two that resigned – to receive $78M in golden ...  Triangle Business Journal
Salix Executives Who Left After Financial Errors Get $46 Million  Bloomberg
Salix Pharmaceuticals, Ltd. (SLXP) Attracts Endo International's (ENDP) Attention
... is in the race to acquire Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP), anonymous sources told Reuters. Endo, which focuses on pain management drugs, sent several letters to Salix, maker of drugs for bowel diseases, only to be rebuffed on many accounts.
Stock Update: Salix Pharmaceuticals Ltd. (NASDAQ:SLXP)  Street Report
Salix Pharmaceuticals (SLXP) Stock Higher Today on Shire Takeover Talk